The combination treatment enhanced granzyme B-dependent T lymphocyte killing by reversing the additive G2/M cell-cycle blockade induced by IR and granzyme B. The combination of IR and AZ1775 improved CD8+ cell-dependent control of MOC1 tumor growth and the rate of complete rejection of established tumors in the context of PD axis ICI. This evidence concerns the gene CD8A and neoplasm.